Cable Hill Partners, LLC Biomarin Pharmaceutical Inc Transaction History

Cable Hill Partners, LLC

$964 Million
Q3 2024

A detailed history of Cable Hill Partners, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Cable Hill Partners, LLC holds 4,330 shares of BMRN stock, worth $270,365. This represents 0.03% of its overall portfolio holdings.

Number of Shares

4,330

Previous 4,338 0.18%

Holding current value

$270,365

Previous $357,000 14.85%

% of portfolio

0.03%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$69.02 - $93.84 $552 - $750	-8 Reduced 0.18%	4,330 $304,000
Q2 2024 Jul 22, 2024	BUY	$74.43 - $92.22 $322,877 - $400,050	4,338 New	4,338 $357,000
Q3 2023 Oct 27, 2023	BUY	$85.07 - $94.48 $2,637 - $2,928	31 Added 0.72%	4,361 $385,000
Q1 2023 May 04, 2023	SELL	$87.74 - $117.27 $27,462 - $36,705	-313 Reduced 6.74%	4,330 $421,000
Q4 2022 Feb 06, 2023	BUY	$80.93 - $108.63 $1,294 - $1,738	16 Added 0.35%	4,643 $480,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $24,401 - $28,791	297 Added 6.86%	4,627 $392,000
Q3 2019 Oct 29, 2019	SELL	$67.4 - $85.11 $4,718 - $5,957	-70 Reduced 1.59%	4,330 $292,000
Q1 2019 May 10, 2019	SELL	$84.2 - $98.62 $4,546 - $5,325	-54 Reduced 1.21%	4,400 $391,000
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $5,071 - $5,708	54 Added 1.23%	4,454 $440,000
Q4 2017 Feb 22, 2018	SELL	$80.76 - $95.13 $4,280 - $5,041	-53 Reduced 1.19%	4,400 $397,000
Q3 2017 Oct 27, 2017	BUY	$80.6 - $94.95 $4,271 - $5,032	53 Added 1.2%	4,453 $414,000
Q2 2017 Aug 14, 2017	BUY	N/A	4,400	4,400 $398,000

Others Institutions Holding BMRN

# of Institutions

645

Shares Held

178M

Call Options Held

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.6B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cable Hill Partners, LLC with notifications on news.

Account

Cable Hill Partners, LLC Biomarin Pharmaceutical Inc Transaction History